Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faropenem medoxomil in AECB
NCT00255983Phase 3Terminated
- Sponsor
- Replidyne, Inc.
- Start
- Dec 2005
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic bronchitis (CB) comparing Faropenem medoxomil with Placebo (2 arms). Primary endpoint: Clinical response at test of cure. Started Dec 2005; status: terminated.
02
Drugs
faropenem medoxomil
03
Conditions
chronic bronchitis (CB)
Beyond the preview
Go deeper on NCT00255983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00255983.